Picard Medical to Showcase New TAH Innovations
Picard Medical, Inc. (NYSE: PMI), known for pioneering the first commercially available total artificial heart, has announced an important presentation regarding its cutting-edge Emperor Total Artificial Heart (TAH). This announcement comes as the company prepares to take part in the upcoming 31st Annual Meeting of the International Society for Mechanical Circulatory Support (ISMCS 2025), set to occur in Vienna, Austria. The event is scheduled from December 1st to 4th.
Highlighting In Vitro Data Presentation
The presentation will unveil significant in vitro performance data of the Emperor TAH, which represents the next step in total artificial heart technology. With this advanced system, the necessity for an external pneumatic driver has been eliminated, enhancing patient comfort and freedom of movement. This innovative approach addresses many of the limitations faced by existing artificial heart patients.
Details of the ISMCS Presentation
The session will take place on Thursday, December 4, 2025, at 14:05 Central European Time (CET). It is categorized as Mini Oral Session 3, focusing on Hemocompatibility and Heart/Pump Interaction. The presentation, titled "The Emperor Total Artificial Heart: A Next Generation, Fully Implantable Total Artificial Heart," will be delivered by Duffy Elmer, Engineering Project Manager at Picard Medical.
Key Features of the Emperor TAH
The Emperor TAH integrates a sophisticated internal motor-driven design that is engineered to provide a seamless experience. This technology is a game-changer for patients suffering from end-stage heart failure, as it aims to significantly elevate their quality of life by allowing greater mobility. Patients can engage more freely in daily activities, alleviating some of the burdens that come with traditional artificial heart systems.
Overview of ISMCS 2025
ISMCS 2025 is an important global platform where leading researchers, clinicians, and engineers converge to discuss advancements and innovations in mechanical circulatory support. This gathering is vital for highlighting new clinical research, sharing insights on emerging technologies, and exploring the latest innovations in medical devices.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent entity of SynCardia Systems, LLC, a leader in total artificial heart technology. The SynCardia Total Artificial Heart (STAH) is the first artificial heart to receive approvals from both the FDA and Health Canada, making it the only commercially available option for patients in the U.S. and Canada. With a track record of over 2,100 successful implants in 27 countries, the STAH remains the most widely utilized artificial heart globally, with extensive clinical research backing its efficacy.
Contact Information
For more details about Picard Medical and its innovative projects, visit www.picardmedical.com or refer to the company’s filings with the U.S. Securities and Exchange Commission.
Frequently Asked Questions
What is the Emperor Total Artificial Heart?
The Emperor TAH is a next-generation artificial heart designed for patients with end-stage heart failure, removing the need for an external driver to enhance mobility.
When and where will the presentation take place?
The presentation will occur on December 4, 2025, at the ISMCS event in Vienna, addressing vital topics around heart and pump interaction.
Who will present the in vitro data?
Duffy Elmer, Engineering Project Manager at Picard Medical, will present the in vitro data during the session.
Where can I learn more about Picard Medical?
Additional information about Picard Medical’s products and initiatives can be found on their official website at www.picardmedical.com.
How does the Emperor TAH improve patient life quality?
The Emperor TAH's design enhances patient comfort and mobility, allowing individuals to engage more freely in everyday activities compared to traditional artificial heart systems.
